Related Experiment Video
Updated: Sep 9, 2025
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic
Mallory R Taylor1,2, James R Anderson3, Julie R Park4
1Department of Pediatrics, Division of Hematology/Oncology, University of Washington, Seattle, Washington, USA.
Background:
Toddlers (age 365-<547 days) with MYCN non-amplified (MYCN-NA) metastatic neuroblastoma (NBL) that have at least one unfavorable biologic feature ("mixed biology toddlers") are a rare NBL subgroup in need of further study.
Methods:
Using the International Neuroblastoma Risk Group (INRG) Data Commons, we identified all toddlers with newly diagnosed metastatic, MYCN-NA NBL. Unfavorable biologic features included (1) unfavorable histology, (2) DNA index ≤1, (3) 1p loss of heterozygosity (LOH), and (4) 11q LOH. Kaplan-Meier curves of event-free survival (EFS) and overall survival (OS) were generated and compared using a log rank test; Cox proportional hazard regression models were used for multivariable analysis.
Results:
Of the 450 patients identified, 157 had ≥1 unfavorable biologic feature and 26 had all favorable features. After adjusting for unfavorable biologic features, only high ferritin and high lactate dehydrogenase (LDH) remained significantly associated with worse EFS and OS. A total of 5-year EFS for mixed biology toddlers was 74.3% versus 88.5% for those with all favorable biologic features; 5-year OS was 79.3% versus 100%, respectively.
Conclusion:
Mixed biology toddlers have lower EFS and OS compared to those whose tumors have favorable biologic features. Inclusion in high-risk NBL trials should be considered for this rare subgroup.
